Memantine Hcs

Memantine Hydrochloride, the active ingredient in Memantine Hcs, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantine Hcs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hcs belongs to the NMDA receptor antagonist class and is used in the management of Alzheimer’s disease. - Moderate Alzheimer’s disease: improves cognitive symptoms and daily functioning. - Severe Alzheimer’s disease: supports functional abilities and may slow decline. - Alzheimer’s disease‑related dementia: may help maintain patient independence.

Memantine Hcs may be associated with a range of adverse reactions.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hypertension: elevated blood pressure. - Stevens‑Johnson syndrome: severe skin reaction.

Before initiating therapy with Memantine Hcs, consider the following precautions. - Renal impairment: assess kidney function and adjust dose if needed. - History of seizures: monitor closely for neurologic events. - Cardiovascular disease: evaluate risk of arrhythmias. - Concomitant NMDA antagonists: avoid duplicate therapy. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine Hcs can interact with several medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Other NMDA receptor antagonists: combined effect can lead to excessive inhibition. - Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce therapeutic benefit. - Diuretics: can alter renal clearance of memantine. - Alcohol: may enhance dizziness and CNS depression.